Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

(2014) Ami V. Desai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ERRATA

(2014)   JOURNAL OF CLINICAL ONCOLOGY

Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody

(2014) H. Xu et al.   Cancer Immunology Research

A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children’s Oncology Group study ANBL00P1

(2013) A E Seif et al.   BONE MARROW TRANSPLANTATION

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial

(2013) Susan G Kreissman et al.   LANCET ONCOLOGY

Neuroblastoma: Issues in Transplantation

(2012) Stephan A. Grupp et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

(2012) Nai-Kong V. Cheung et al.   OncoImmunology

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

(2011) Thorsten Simon et al.   BMC CANCER

Identification of tumoral glial precursor cells in neuroblastoma

(2011) Sandra Acosta et al.   CANCER LETTERS

Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study

(2011) Julie R. Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Interleukin-15 biology and its therapeutic implications in cancer

(2011) Jason C. Steel et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion

(2010) Ruth Ladenstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study

(2009) Katherine K. Matthay et al.   JOURNAL OF CLINICAL ONCOLOGY

28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures

(2008) R Ladenstein et al.   BONE MARROW TRANSPLANTATION

Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

(2008) Andrew L. Gilman et al.   JOURNAL OF CLINICAL ONCOLOGY